NYSE · BSX
Healthcare · Medical - Devices
$42.69
Up+$0.26 (+0.61%)
Updated Oct 30, 2026, 8:00 AM
SID Score
4.9/10
Composite research score
Smart Money
63/100
Neutral
Price performance · BSX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
BSX closed at $42.69 after 21 trading sessions, down 1.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $41.81 | $43.085 | $41.675 | $42.69 | 31.76M |
| Oct 28, 2026 | $41.95 | $43.915 | $39.57 | $42.43 | 69.84M |
| Oct 27, 2026 | $45.29 | $45.33 | $44.855 | $45.06 | 15.14M |
| Oct 26, 2026 | $45.31 | $46.07 | $45.125 | $45.58 | 11.93M |
| Oct 23, 2026 | $45.84 | $46.16 | $45.215 | $45.69 | 8.77M |
| Oct 22, 2026 | $44.72 | $46.05 | $44.62 | $46.01 | 16.4M |
| Oct 21, 2026 | $45.04 | $45.64 | $43.915 | $44.51 | 15.19M |
| Oct 20, 2026 | $45.67 | $46.045 | $45.15 | $45.58 | 16.01M |
| Oct 19, 2026 | $44.01 | $45.10 | $43.935 | $45.05 | 13.97M |
| Oct 16, 2026 | $44.45 | $44.8314 | $43.89 | $44.39 | 12.41M |
| Oct 15, 2026 | $43.945 | $44.43 | $43.46 | $44.14 | 15.87M |
| Oct 14, 2026 | $43.40 | $43.5785 | $42.28 | $43.00 | 15.1M |
| Oct 13, 2026 | $43.95 | $44.1522 | $42.455 | $43.31 | 14.28M |
| Oct 12, 2026 | $43.10 | $43.92 | $42.67 | $43.84 | 13.6M |
| Oct 9, 2026 | $42.12 | $42.83 | $41.97 | $42.73 | 13.04M |
| Oct 8, 2026 | $41.50 | $42.27 | $41.385 | $42.04 | 22.88M |
| Oct 7, 2026 | $42.19 | $42.515 | $41.50 | $41.58 | 15.89M |
| Oct 6, 2026 | $42.47 | $42.75 | $41.995 | $42.19 | 12.55M |
| Oct 5, 2026 | $42.53 | $43.30 | $42.285 | $42.40 | 13.74M |
| Oct 2, 2026 | $43.315 | $43.44 | $41.9397 | $42.60 | 18.31M |
| Oct 1, 2026 | $43.51 | $43.96 | $42.95 | $43.23 | 17.94M |
The latest Smart Investors Daily articles mentioning BSX.
Company
Market Activity
Research & News
BSX research
Company profile and research snapshot.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | UBS | Buy | — |
| Oct 29, 2026 | Leerink Partners | Outperform | — |
| Oct 29, 2026 | Citigroup | Neutral | — |
| Oct 29, 2026 | RBC Capital | Outperform | — |
| Oct 29, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
Yahoo · Oct 22, 2026
Boston Scientific has seen its share price fall sharply over the past year, even as the business pushes deeper into higher end medical devices like neuromodulation. That slide raises a simple question for you as an investor: does the current valuation still line up with the cash the company is expected to generate over time? The stock is down 57.1% over the past year, which puts the focus firmly on whether the recent share price now fully reflects its cash flow profile. Boston Scientific's...
Yahoo · Oct 22, 2026
The global gastric device market is forecast to inch from over $124 million in 2025 to about $134 million by 2032, a new Research and Markets report finds, as weight-loss drugs and bariatric surgery compete with balloons and bands from Allurion, Boston Scientific and Medtimo.Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Gastric Device Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Gastric Bands and Gastric Balloons" has been added to ResearchAndMarkets.com's offering. The glo
Yahoo · Oct 22, 2026
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BSX.
